Smart Inhalers Market Overview:
Global smart inhalers market is estimated to reach $191 million by 2022, growing at a CAGR of 63.3% during 2016 to 2022, in the moderate growth scenario. Smart inhalers are also known as connected inhalers andsensors and are mainly used as clip-on sensors, which are attached over a normal inhaler (DPIs, MDIs) or nebulizers for the treatment of asthma and COPD. Smart inhalers as defined in this report are defined as devices providing data wirelessly through cloud, internet, or mobile apps. They track the usage of the dose as and when taken by the patients and also alert the patients through timely reminders. Under the scope of study, the report only considers devices that provides data digitally and excludes devices such as traditional inhalers or which do not use smart inhalers. In addition, smart inhalers available for commercial use as well as smart inhalers used for research and development are considered in the report.
The Global smart inhalers market is segmented under three different scenarios: moderate growth scenario, rapid growth scenario, and diminishing growth scenario.
Market growth is attributed to the increase in air pollution, incidence of respiratory diseases such as asthma and COPD, and healthcare burden, due to higher cases of asthma and COPD. In addition, probable increase in adherence to smart inhalers is an additional factor for the growth. However, high cost of asthma and COPD treatment, limited availability of smart inhalers, and misuse of data are expected to restrain the market growth.
Global Smart Inhalers Market Segmentation
SMART INHALERS MARKET: SEGMENTATION
TOP INVESTMENT POCKETS:
The smart inhalers market is based on three different scenarios, and therefore top investment pockets have been mentioned with respect to the moderate growth scenario.
North America accounted for the maximum revenue due to wider availability of smart inhalers coupled with wider government initiatives, growth in demand for advanced technology, and increase in use of mobile phones. Smart inhalers directly transfer data related to the medications to the mobile app as well as to the cloud server through the Internet. Therefore, higher use of mobile phones coupled with rise in cases of asthma and COPD in this region act as major growth opportunities for the smart inhalers market.
SMART INHALERS, BY PRODUCT
Inhalation route is the fastest and most effective method of delivering medications to the respiratory system to treat COPD and asthma. These medications are delivered orally through inhalers; however, patients and users tend to forget or miss the dose for the indication. This has led to the development of smart inhalers, which can be easily attached to the patients inhaler and monitor adherence as well as record the time of each dose when taken. Smart inhalers have emerged as a novel approach in asthma and COPD management and are expected to be a potential factor in the growth of the market.
REGIONAL AND COUNTRY OVERVIEW:
Europe has emerged as the second preferred market for smart inhaler products. Novartis, AstraZeneca, and Boehringer Ingelheim are key players the European region. Adoption of these smart inhalers, by hospitals and patients boosts the market growth. Moreover, the European Academy of Allergy & Clinical Immunology is continuously making efforts to increase awareness about asthma and COPD.
In the year 2015, the leading revenue-generating region was North America, whereas Asia-Pacific is projected to grow at a significant CAGR of 65.3% during the forecast period, due to rise in demand for smart inhalers and increase in cases of COPD and asthma. Asia-Pacific is the potential market for growth of smart inhalers due to high population base, high disposable incomes, and rise in patient awareness, and increase in prevalence of asthma and COPD.
The Turkish smart inhalers market was valued at $30 thousand in 2015, and is expected to reach $1,090 thousand by 2022, with a CAGR of 65.3% during the forecast period.
TURKEY: SMART INHALER MARKET SIZE, 20142022
Adherium is the leading player in the smart inhaler market with majority product approvals. However, smart inhalers being a lucrative market, acquisitions & collaborations between the pharmaceutical companies, medical device companies, and smart inhaler manufacturers are increasing to capture market space. Increase in collaborations between pharmaceutical companies and smart inhalers manufacturers, such as collaboration between Adherium & AstraZeneca; and GSK partnering with Propeller Health, have led competition in the industry. Major players have adopted product approval and clinical trials as their key development strategies. Important players operating in this market include Teva Pharmaceutical Industries Ltd. (Gecko Health Innovations), Vectura Group plc., Boehringer Ingelheim GmbH, AstraZeneca plc, Cohero Health, LLC; Propeller Health, OPKO Health, Inc. (Inspiro Medical Ltd.), Adherium Limited, Novartis AG, and GlaxoSmithKline plc.
SMART INHALERS MARKET KEY BENEFITS
- Competitive landscape section includes major players operating within the smart inhalers market, with key strategies adopted by them to achieve high monetary value.
- The report also provides quantitative as well as qualitative trends to assist the stakeholders to understand the situations prevailing in the market.
- Entire projections presented in the report are based on analysis of the current trends and highlight the market potential from 2016 to 2022, both in terms of value and volume.
- The report provides an in-depth analysis of the estimated revenues generated by smart inhalers as well as major geographies during the forecast period.
SMART INHALERS MARKET KEY SEGMENTS:
- Dry Powder Inhalers (DPIs)
- Metered Dose Inhalers (MDIs)
By End User
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Saudi Arabia
- Rest of LAMEA